|
1
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Johnson DR and O'Neill BP: Glioblastoma
survival in the United States before and during the temozolomide
era. J Neurooncol. 107:359–364. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Friedmann-Morvinski D, Narasimamurthy R,
Xia Y, Myskiw C, Soda Y and Verma IM: Targeting NF-κB in
glioblastoma: A therapeutic approach. Sci Adv. 2:e15012922016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Campos B, Wan F, Farhadi M, Ernst A,
Zeppernick F, Tagscherer KE, Ahmadi R, Lohr J, Dictus C, Gdynia G,
et al: Differentiation therapy exerts antitumor effects on
stem-like glioma cells. Clin Cancer Res. 16:2715–2728. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cancer Genome Atlas Research Network, .
Comprehensive genomic characterization defines human glioblastoma
genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sundar SJ, Hsieh JK, Manjila S, Lathia JD
and Sloan A: The role of cancer stem cells in glioblastoma.
Neurosurg Focus. 37:E62014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Auffinger B, Tobias AL, Han Y, Lee G, Guo
D, Dey M, Lesniak MS and Ahmed AU: Conversion of differentiated
cancer cells into cancer stem-like cells in a glioblastoma model
after primary chemotherapy. Cell Death Differ. 21:1119–1131. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Olmez I, Shen W, McDonald H and Ozpolat B:
Dedifferentiation of patient-derived glioblastoma multiforme cell
lines results in a cancer stem cell-like state with
mitogen-independent growth. J Cell Mol Med. 19:1262–1272. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lathia JD, Hitomi M, Gallagher J, Gadani
SP, Adkins J, Vasanji A, Liu L, Eyler CE, Heddleston JM, Wu Q, et
al: Distribution of CD133 reveals glioma stem cells self-renew
through symmetric and asymmetric cell divisions. Cell Death Dis.
2:e2002011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
O'Brien CA, Kreso A, Ryan P, Hermans KG,
Gibson L, Wang Y, Tsatsanis A Gallinger S and Dick JE: ID1 and ID3
regulate the self-renewal capacity of human colon cancer-initiating
cells through p21. Cancer Cell. 21:777–792. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pece S, Tosoni D, Confalonieri S, Mazzarol
G, Vecchi M, Ronzoni S, Bernard L, Viale G, Pelicci PG and Di Fiore
PP: Biological and molecular heterogeneity of breast cancers
correlates with their cancer stem cell content. Cell. 140:62–73.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sugiarto S, Persson AI, Munoz EG,
Waldhuber M, Lamagna C, Andor N, Hanecker P, Ayers-Ringler J,
Phillips J, Siu J, et al: Asymmetry-defective oligodendrocyte
progenitors are glioma precursors. Cancer Cell. 20:328–340. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang M, Song T, Yang L, Chen R, Wu L,
Yang Z and Fang J: Nestin and CD133: Valuable stem cell-specific
markers for determining clinical outcome of glioma patients. J Exp
Clin Cancer Res. 27:852008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Karsy M, Albert L, Tobias ME, Murali R and
Jhanwar-Uniyal M: All-trans retinoic acid modulates cancer stem
cells of glioblastoma multiforme in an MAPK-dependent manner.
Anticancer Res. 30:4915–4920. 2010.PubMed/NCBI
|
|
16
|
Yu SC, Ping YF, Yi L, Zhou ZH, Chen JH,
Yao XH, Gao L, Wang JM and Bian XW: Isolation and characterization
of cancer stem cells from a human glioblastoma cell line U87.
Cancer Lett. 265:124–134. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun Y, Goderie SK and Temple S: Asymmetric
distribution of EGFR receptor during mitosis generates diverse CNS
progenitor cells. Neuron. 45:873–886. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Singh SK, Clarke ID, Terasaki M, Bonn VE,
Hawkins C, Squire J and Dirks PB: Identification of a cancer stem
cell in human brain tumors. Cancer Res. 63:5821–5828.
2003.PubMed/NCBI
|
|
19
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Howard CM, Valluri J, Alberico A, Julien
T, Mazagri R, Marsh R, Alastair H, Cortese A, Griswold M, Wang W,
et al: Analysis of Chemopredictive assay for targeting cancer stem
cells in glioblastoma patients. Transl Oncol. 10:241–254. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng X, Shen G, Yang X and Liu W: Most C6
cells are cancer stem cells: Evidence from clonal and population
analyses. Cancer Res. 67:3691–3697. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen J, Li Y, Yu TS, McKay RM, Burns DK,
Kernie SG and Parada LF: A restricted cell population propagates
glioblastoma growth after chemotherapy. Nature. 488:522–526. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu Y, Richard JP, Wang SD, Rath P, Laterra
J and Xia S: Regulation of glioblastoma multiforme stem-like cells
by inhibitor of DNA binding proteins and oligodendroglial
lineage-associated transcription factors. Cancer Sci.
103:1028–1037. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Joo KM, Kim SY, Jin X, Song SY, Kong DS,
Lee JI, Jeon JW, Kim MH, Kang BG, Jung Y, et al: Clinical and
biological implications of CD133-positive and CD133-negative cells
in glioblastomas. Lab Invest. 88:808–815. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Clement V, Dutoit V, Marino D, Dietrich PY
and Radovanovic I: Limits of CD133 as a marker of glioma
self-renewing cells. Int J Cancer. 125:244–248. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang J, Sakariassen PØ, Tsinkalovsky O,
Immervoll H, Bøe SO, Svendsen A, Prestegarden L, Røsland G, Thorsen
F, Stuhr L, et al: CD133 negative glioma cells form tumors in nude
rats and give rise to CD133 positive cells. Int J Cancer.
122:761–768. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Barrantes-Freer A, Renovanz M, Eich M,
Braukmann A, Sprang B, Spirin P, Pardo LA, Giese A and Kim EL:
CD133 expression is not synonymous to immunoreactivity for AC133
and fluctuates throughout the cell cycle in glioma stem-like cells.
PLoS One. 10:e01305192015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiang X, Xing H, Kim TM, Jung Y, Huang W,
Yang HW, Song S, Park PJ, Carroll RS and Johnson MD: Numb regulates
glioma stem cell fate and growth by altering epidermal growth
factor receptor and Skp1-Cullin-F-box ubiquitin ligase activity.
Stem Cells. 30:1313–1326. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Di Marcotullio L, Greco A, Mazzá D,
Canettieri G, Pietrosanti L, Infante P, Coni S, Moretti M, De
Smaele E, Ferretti E, et al: Numb activates the E3 ligase Itch to
control Gli1 function through a novel degradation signal. Oncogene.
30:65–76. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Beres BJ, George R, Lougher EJ, Barton M,
Verrelli BC, McGlade CJ, Rawls JA and Wilson-Rawls J: Numb
regulates Notch1, but not Notch3, during myogenesis. Mech Dev.
128:247–257. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shen Q, Zhong W, Jan YN and Temple S:
Asymmetric Numb distribution is critical for asymmetric cell
division of mouse cerebral cortical stem cells and neuroblasts.
Development. 129:4843–4853. 2002.PubMed/NCBI
|
|
32
|
Bajaj J, Zimdahl B and Reya T: Fearful
symmetry: Subversion of asymmetric division in cancer development
and progression. Cancer Res. 75:792–797. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Euskirchen P, Skaftnesmo KO, Huszthy PC,
Brekkå N, Bjerkvig R, Jacobs AH and Miletic H: NUMB does not impair
growth and differentiation status of experimental gliomas. Exp Cell
Res. 317:2864–2873. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Beier CP and Beier D: CD133 negative
cancer stem cells in glioblastoma. Front Biosci (Elite Ed).
3:701–710. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schenk T, Stengel S and Zelent A:
Unlocking the potential of retinoic acid in anticancer therapy. Br
J Cancer. 111:2039–2045. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ling GQ, Liu YJ, Ke YQ, Chen L, Jiang XD,
Jiang CL and Ye W: All-trans retinoic acid impairs the vasculogenic
mimicry formation ability of U87 stem-like cells through promoting
differentiation. Mol Med Rep. 12:165–172. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Friedman MD, Jeevan DS, Tobias M, Murali R
and Jhanwar-Uniyal M: Targeting cancer stem cells in glioblastoma
multiforme using mTOR inhibitors and the differentiating agent
all-trans retinoic acid. Oncol Rep. 30:1645–1650. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bu P, Chen KY, Lipkin SM and Shen X:
Asymmetric division: A marker for cancer stem cells in early stage
tumors? Oncotarget. 4:950–951. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Armstrong JL, Taylor GA, Thomas HD, Boddy
AV, Redfern CP and Veal GJ: Molecular targeting of retinoic acid
metabolism in neuroblastoma: The role of the CYP26 inhibitor
R116010 in vitro and in vivo. Br J Cancer. 96:1675–1683. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chakravarti N, Lotan R, Diwan AH, Warneke
CL, Johnson MM and Prieto VG: Decreased expression of retinoid
receptors in melanoma: Entailment in tumorigenesis and prognosis.
Clin Cancer Res. 13:4817–4824. 2007. View Article : Google Scholar : PubMed/NCBI
|
